Financial Data
KPTI Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
KPTIKaryopharm Therapeutics Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum29
- Value65
- Quality100
- Risk resilience32
- Sentiment—
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 23, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | $33.43M | $35.07M | $34.08M |
| Gross Profit | $32.35M | $33.71M | $32.6M |
| Operating Income | -$22.53M | -$26.76M | -$17.84M |
| Net Income | -$67.02M | -$22.39M | -$102.2M |
| EPS | -$2.32 | -$1.02 | -$15.16 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Operating Cash Flow | -$24.93M | -$22.73M | -$11.83M | -$5.86M |
| Capital Expenditure | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$24.93M | -$22.73M | -$11.83M | -$5.86M |
| Net Cash Provided By Operating Activities | -$24.93M | -$22.73M | -$11.83M | -$5.86M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Total Assets | $111.32M | $131.42M | $117.46M |
| Total Debt | $215.89M | $230.87M | $226.4M |
| Cash And Cash Equivalents | — | — | — |
| Total Liabilities | $441.49M | $397.06M | $401.34M |
| Total Stockholders Equity | -$330.17M | -$265.65M | -$283.89M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| P/E ratio | -1.05 | -1.37 | -0.12 | -0.43 |
| P/B ratio | -0.86 | -0.46 | -0.17 | -0.21 |
| P/S ratio | 8.46 | 3.5 | 1.46 | 1.29 |
| Debt To Equity | -0.65 | -0.87 | -0.8 | -0.73 |
| Free Cash Flow Yield | -8.82% | -18.54% | -23.84% | -10.34% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| P/E ratio | -1.05 | -1.37 | -0.12 | -0.43 |
| P/B ratio | -0.86 | -0.46 | -0.17 | -0.21 |
| P/S ratio | 8.46 | 3.5 | 1.46 | 1.29 |
| Return On Equity | 20.30% | 8.43% | 34.89% | 12.30% |
| Debt To Equity | -0.65 | -0.87 | -0.8 | -0.73 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | -0.08x |
| Pb | -0.16x |
| Gross Margin | 95.88% |
| Operating Margin | -56.17% |
| ROE | 77.63% |
| ROIC | 376.87% |
| Debt To Equity | -0.65 |
| FCF Yield | -155.86% |
As of Oct 22, 2026
| Metric | Value |
|---|---|
| Close | $0.55 |
| Volume | 7.36M |
| RSI (14) | 34.32 |
| MACD | -0.37 |
| MACD signal | -0.42 |
| MACD histogram | 0.05 |
| ADX (14) | 61.5 |
| SMA (50) | $1.38 |
| SMA (200) | $6.26 |
| ATR (14) | $0.13 |
| Historical volatility (annualized) | 238.07% |
| Volume (20-day average) | 1.8M |
As of Oct 22, 2026
| Metric | Value |
|---|---|
| Resilience score | 32/100 |
| Beta | 1.04 |
| Annual volatility | 128.22% |
| Max Drawdown | -97.05% |
| Sharpe Ratio | -1.06 |
| VaR (95%, 1-day) | -10.30% |
As of Oct 22, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
KPTI Financial Data FAQ
What is Karyopharm Therapeutics Inc.'s revenue?
Karyopharm Therapeutics Inc.'s revenue is one of the core financial data points for KPTI. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Karyopharm Therapeutics Inc.'s revenue growing?
Revenue growth shows whether Karyopharm Therapeutics Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is KPTI's EPS?
KPTI's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Karyopharm Therapeutics Inc.'s net income?
Karyopharm Therapeutics Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Karyopharm Therapeutics Inc. generate?
Free cash flow shows how much cash Karyopharm Therapeutics Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Karyopharm Therapeutics Inc. have?
Cash and debt help frame KPTI's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.